Dizal (Jiangsu) Pharmaceutical Co. Ltd. A

688192 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

64.11CNY-0.99 (-1.52%)

Price History

Full chart

Market Stats

Previous Close65.10

Open64.57

Day Range63.40 – 66.48

52-Week Range35.73 – 73.00

Volume6.70M

Market Cap26.98B

P/E (TTM)0.00

Forward P/E0.00

EPS-1.29

Dividend Yield0.00%

Beta-0.01

50-Day Avg56.96

200-Day Avg54.20

About

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEODr. Zhang Xiaolin Ph.D.
Employees990
HeadquartersNo. 199 and 245 Liangjing Rd, Shanghai, China, 201203, China
Websitehttps://www.dizalpharma.com

Leadership

Dr. Zhang Xiaolin Ph.D.GM & Chairman · b. 1964
Mr. Lyu Hongbin M.B.A.CFO & Board Secretary · b. 1978
Ms. Zhiwei ZhangDeputy GM, VP & Head of Operations · b. 1982
Dr. Qingbei Zeng Ph.D.Deputy GM, Chief Scientist & Senior VP · b. 1962
Dr. Zhenfan Yang M.D., Ph.D.Deputy GM & Chief Medical Officer · b. 1968
Ms. Qingyi WuDeputy GM & Chief Commercial Officer · b. 1974
Dr. Honchung TsuiDeputy GM, Senior VP & Head of Medicinal Chemistry Department · b. 1968
Dr. Shih-Ying Chang Ph.D.Deputy GM, VP and Head of Chemistry, Production & Control Department · b. 1963
Ms. Suqin ChenDeputy GM & Senior VP of Clinical Operations · b. 1967
Mr. Weijun QiaoVP & Head of Registration Affairs · b. 1966

Financials

Income Statement

Currency: CNY	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	41.02M	27.76M	10.29M	0	91.29M	359.90M	801.14M
Growth (%)	-	-32.32%	-62.95%	-100.00%	-	+294.24%	+122.60%
Cost of Revenue	35.83M	24.30M	9.01M	-	3.21M	9.32M	34.23M
Gross Profit	5.19M	3.46M	1.28M	0	88.07M	350.58M	766.91M
Gross Margin	12.66%	12.47%	12.42%	-	96.48%	97.41%	95.73%
Operating Expense	455.55M	763.83M	666.18M	786.19M	1.21B	1.28B	1.53B
Operating Income	-450.36M	-760.37M	-664.90M	-786.19M	-1.12B	-932.84M	-760.33M
Operating Margin	-1097.97%	-2738.99%	-6464.47%	-	-1231.58%	-259.19%	-94.91%
EBITDA	-427.04M	-730.55M	-613.08M	-672.97M	-1.03B	-850.53M	-667.20M
EBITDA Margin	-1041.12%	-2631.57%	-5960.68%	-	-1133.17%	-236.32%	-83.28%
Net Income	-445.75M	-586.61M	-669.88M	-736.00M	-1.11B	-845.96M	-764.05M
Net Income Margin	-1086.74%	-2113.09%	-6512.85%	-	-1213.42%	-235.05%	-95.37%
R&D	421.44M	439.49M	587.60M	664.52M	805.60M	723.69M	855.61M
R&D as % of Total Revenue	1027.45%	1583.15%	5712.89%	-	882.47%	201.08%	106.80%
Interest Expense	-	-	3.07M	4.34M	7.57M	22.75M	31.22M
Interest Expense % of Total Revenue	-	-	29.83%	-	8.30%	6.32%	3.90%

Balance Sheet

Currency: CNY	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	627.36M	1.22B	2.75B	2.08B	1.50B	1.72B	3.00B
Total Liabilities	176.96M	136.41M	282.91M	323.43M	647.75M	1.52B	1.71B
Total Equity	450.40M	1.08B	2.46B	1.76B	848.63M	193.76M	1.29B
Cash	206.88M	509.02M	364.24M	121.67M	74.20M	250.16M	291.42M
Net Debt	-	-	-	-	264.23M	807.42M	614.18M

Cash Flow

Currency: CNY	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-365.63M	-410.01M	-492.28M	-603.37M	-967.88M	-650.53M	-588.32M
Capital Expenditure	13.83M	211.73M	8.98M	73.78M	32.13M	137.58M	170.47M
Free Cash Flow	-379.45M	-621.75M	-501.26M	-677.15M	-1.00B	-788.10M	-758.79M
Dividends Paid	-	-	52.24K	-	3.38M	20.55M	32.89M
FCF to OCF	103.78%	151.64%	101.83%	112.23%	103.32%	121.15%	128.98%
Dividend Paid to FCF	-	-	-0.01%	-	-0.34%	-2.61%	-4.33%

Earnings

Report Date	Feb 26, 2022	Apr 27, 2022	Aug 25, 2022	Oct 28, 2022	Mar 23, 2023	Apr 28, 2023
EPS Estimate	-	-	-	-	-	-
EPS Actual	-0.50	-0.45	-0.40	-0.41	-0.56	-0.59
Surprise	-	-	-	-	-	-
Timing	Pre-market	Pre-market	Pre-market	After-hours	After-hours	Pre-market

Key Statistics & Ratios

Market Cap26.98B

Enterprise Value27.65B

Trailing P/E0.00

Forward P/E0.00

Price / Sales27.85

Price / Book24.80

EPS-1.29

Book Value2.43

Revenue (TTM)968.83M

Gross Profit (TTM)929.33M

EBITDA-609.60M

Profit Margin-61.63%

Operating Margin-45.08%

Return on Equity-43.70%

Return on Assets-13.68%

Shares Outstanding465.17M

Shares Float168.39M

Beta-0.01

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%